The global pandemic disrupted business operations and exposed supply chains that were fine-tuned for efficiency but not resilience. Today, the war in Ukraine and the recent lockdowns in China have again put entire value chains under stress.
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer.
Across the world, local officials and NGO workers are heroically responding to overlapping, complex crises. The energy and determination of these frontline organizations is unmatched, but their technical capacity can fall short in crucial ways.